Kelzyn (Dienogest, Ethinylestradiol | Lactose)

Kelzyn, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent ovulation and regulate menstrual cycles.

• Prevention of pregnancy: suppresses ovulation and creates an unfavorable uterine environment, providing reliable birth control.
• Dysmenorrhea: reduces menstrual pain by stabilizing hormonal fluctuations.
• Irregular menstrual bleeding: normalizes cycle length and flow, improving menstrual regularity.

• Dienogest/Ethinylestradiol combines a progestogenic component (dienogest) with an estrogen (ethinylestradiol). The estrogen suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), while the progestogen reinforces the inhibition of ovulation, thickens cervical mucus, and induces endometrial changes that prevent fertilisation and implantation. It also provides negative feedback to the hypothalamus, reducing gonadotropin‑releasing hormone release, which further stabilises the hormonal milieu.

Kelzyn may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset, often transient.
• Breast tenderness: discomfort or swelling of the breasts.
• Headache: mild to moderate intensity.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or emotional fluctuations.
• Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or myocardial infarction.
• Hypertension: significant increase in blood pressure.
• Liver disorders: jaundice or hepatic dysfunction.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Visual disturbances: sudden loss of vision or eye pain.

Before prescribing Kelzyn, clinicians should evaluate several safety considerations.

• Pregnancy contraindication: the product must not be used during pregnancy (Category X).
• Smoking in women over 35: increases risk of cardiovascular events; avoid use.
• History of thromboembolism: contraindicated due to elevated clotting risk.
• Liver disease: impaired metabolism may increase adverse effects.
• Hypertension: monitor blood pressure regularly.
• Breast cancer history: avoid use as estrogen component may stimulate tumor growth.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Kelzyn can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., phenytoin, carbamazepine): markedly reduce contraceptive efficacy.
• Antiretroviral agents (e.g., efavirenz): decrease hormone levels, risking breakthrough ovulation.
• St John’s wort: herbal inducer that lowers plasma concentrations of the active ingredients.

Moderate Interactions (Monitor Closely)

• Antibiotics (tetracycline, doxycycline): may slightly diminish contraceptive effect.
• Antifungal agents (ketoconazole, itraconazole): can increase hormone levels, raising side‑effect risk.
• SSRIs (e.g., fluoxetine): may affect bleeding patterns.
• Diuretics (e.g., spironolactone): can alter fluid balance and blood pressure.
• NSAIDs (e.g., ibuprofen): may increase risk of hypertension.